Literature DB >> 3500182

Sex steroids and bone mass. A study of changes about the time of menopause.

C Slemenda1, S L Hui, C Longcope, C C Johnston.   

Abstract

To examine the relationships between bone loss and sex steroids, 84 peri- and postmenopausal women were studied at 4-mo intervals for 3 yr. At each visit, measurements were made of bone mass at the midshaft and distal radius, of steroids, of gonadotropins, and of bone gla protein (BGP). Bone loss was approximately 1% per yr among late perimenopausal and postmenopausal groups, whereas the early perimenopausal group lost no bone. Mean serum estrogen and BGP concentrations predicted rates of bone loss. BGP was negatively correlated with the rate of bone loss (r = -0.45) and with mean estrogen concentrations (r = -0.40). Multivariate regressions showed estrogen concentrations to be strong independent predictors of the slope of bone mass over time. When BGP concentrations were added to the models, the significance of estrogen was reduced, suggesting that a portion of the estrogen effect was mediated through effects on rates of bone remodelling.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3500182      PMCID: PMC442379          DOI: 10.1172/JCI113201

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  The distribution of cortical and trabecular bone mass along the lengths of the radius and ulna and the implications for in vivo bone mass measurements.

Authors:  R A Schlenker; W W VonSeggen
Journal:  Calcif Tissue Res       Date:  1976-04-13

2.  The effects of synthetic estrogens on the metabolic clearance and production rates of estrone and estradiol.

Authors:  C Longcope; D Watson; K I Williams
Journal:  Steroids       Date:  1974-07       Impact factor: 2.668

Review 3.  Steroid dynamics under steady-state conditions.

Authors:  D T Baird; R Horton; C Longcope; J F Tait
Journal:  Recent Prog Horm Res       Date:  1969

Review 4.  Steroid prehormones.

Authors:  D Baird; R Horton; C Longcope; J F Tait
Journal:  Perspect Biol Med       Date:  1968       Impact factor: 1.416

5.  Effects of artificial menopause on plasma and urine calcium and phosphate.

Authors:  J C Gallagher; M M Young; B E Nordin
Journal:  Clin Endocrinol (Oxf)       Date:  1972-01       Impact factor: 3.478

6.  Serum concentrations of estrogen, testosterone, and gonadotropins in osteoporotic and nonosteoporotic postmenopausal women.

Authors:  B L Riggs; R J Ryan; H W Wahner; N S Jiang; V R Mattox
Journal:  J Clin Endocrinol Metab       Date:  1973-06       Impact factor: 5.958

7.  The effect of long-term mestranol administration on calcium and phosphorus homeostasis in oophorectomized women.

Authors:  J M Aitken; D M Hart; D A Smith
Journal:  Clin Sci       Date:  1971-09       Impact factor: 6.124

Review 8.  A unified concept of osteoporosis.

Authors:  R P Heaney
Journal:  Am J Med       Date:  1965-12       Impact factor: 4.965

9.  Rates of bone loss in the appendicular and axial skeletons of women. Evidence of substantial vertebral bone loss before menopause.

Authors:  B L Riggs; H W Wahner; L J Melton; L S Richelson; H L Judd; K P Offord
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

10.  Conversion of blood androgens to estrogens in normal adult men and women.

Authors:  C Longcope; T Kato; R Horton
Journal:  J Clin Invest       Date:  1969-12       Impact factor: 14.808

View more
  68 in total

1.  Effect of prior treatment with resveratrol on density and structure of rat long bones under tail-suspension.

Authors:  Caroline Habold; Iman Momken; Ali Ouadi; Virgile Bekaert; David Brasse
Journal:  J Bone Miner Metab       Date:  2010-05-11       Impact factor: 2.626

2.  Efficacy and harms of nasal calcitonin in improving bone density in young patients with inflammatory bowel disease: a randomized, placebo-controlled, double-blind trial.

Authors:  Helen M Pappa; Tracee M Saslowsky; Rajna Filip-Dhima; Diane DiFabio; Hajar Hassani Lahsinoui; Apurva Akkad; Richard J Grand; Catherine M Gordon
Journal:  Am J Gastroenterol       Date:  2011-04-26       Impact factor: 10.864

3.  Endogenous sex hormones and bone mineral density among community-based postmenopausal women.

Authors:  S Murphy; K T Khaw; M J Sneyd; J E Compston
Journal:  Postgrad Med J       Date:  1992-11       Impact factor: 2.401

4.  Biochemical markers of bone turnover predict bone loss in perimenopausal women but not in postmenopausal women-the Japanese Population-based Osteoporosis (JPOS) Cohort Study.

Authors:  M Iki; A Morita; Y Ikeda; Y Sato; T Akiba; T Matsumoto; H Nishino; S Kagamimori; Y Kagawa; H Yoneshima
Journal:  Osteoporos Int       Date:  2006-05-03       Impact factor: 4.507

5.  Is there a causal role for IL-1 in postmenopausal bone loss?

Authors:  R Pacifici
Journal:  Calcif Tissue Int       Date:  1992-04       Impact factor: 4.333

6.  Potential value of urinary oestrogen assays in the identification of fast bone losers after the menopause.

Authors:  M H Walkinshaw; P A Mole; C R Paterson
Journal:  Osteoporos Int       Date:  1992-07       Impact factor: 4.507

7.  Serum bone Gla protein in streak gonad syndrome.

Authors:  J Zséli; P Bösze; P Lakatos; P Vargha; G Tarján; E Kollin; C Horváth; J László; I Holló
Journal:  Calcif Tissue Int       Date:  1991-06       Impact factor: 4.333

8.  Cigarette smoking, steroid hormones, and bone mineral density in young women.

Authors:  M Daniel; A D Martin; D T Drinkwater
Journal:  Calcif Tissue Int       Date:  1992-04       Impact factor: 4.333

9.  Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment.

Authors:  R Civitelli; S Gonnelli; F Zacchei; S Bigazzi; A Vattimo; L V Avioli; C Gennari
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

10.  Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats.

Authors:  R B Kimble; J L Vannice; D C Bloedow; R C Thompson; W Hopfer; V T Kung; C Brownfield; R Pacifici
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.